Breaking News Instant updates and real-time market news.

GSK

GlaxoSmithKline

$37.43

-0.36 (-0.95%)

, INVA

Innoviva

$10.21

-0.13 (-1.26%)

05:30
12/02/16
12/02
05:30
12/02/16
05:30

GSK, Innoviva announce Relvar Ellipta approved in Japan for patients with COPD

GlaxoSmithKline plc (GSK) and Innoviva (INVA) announced that the Japanese Ministry of Health, Labour and Welfare has approved Relvar Ellipta for the relief of various symptoms with chronic obstructive pulmonary disease.

GSK

GlaxoSmithKline

$37.43

-0.36 (-0.95%)

INVA

Innoviva

$10.21

-0.13 (-1.26%)

GSK GlaxoSmithKline
$37.43

-0.36 (-0.95%)

09/23/16
09/23/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Morgan Stanley analyst Brian Nowak initiated Activision Blizzard (ATVI) and Electronic Arts (EA), both with Overweight ratings. The analyst is bullish on the digital gaming shift away from "units sold" to a business model based on users, engagement, and digital monetization. He sees digital in-game offerings resulting in recurring and growth user bases, increased per-game engagement, and further monetization opportunities. 2. AstraZeneca (AZN) and GlaxoSmithKline (GSK) both initiated with Overweight ratings by Piper Jaffray analyst Richard Purkiss. 3. Achillion (ACHN) initiated with an Outperform by Wedbush analyst Heather Behanna, who set a $13 price target on the shares. 4. Sysco (SYY) initiated with an Underweight at Barclays and $48 price target by analyst Karen Short. 5. Five Below (FIVE), Dollar Tree (DLTR) and Dollar General (DG) all initiated with Equal Weight ratings by Barclays analyst Karen Short. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/03/16
RBCM
10/03/16
NO CHANGE
Target $95
RBCM
Outperform
Gilead HIV franchise could see risk from competitor data, says RBC Capital
RBC Capital analyst Michael Yee said his conversations with doctors leads him to think two dolutegravir HIV "doublet" studies being conducted by GlaxoSmithKline (GSK) and ViiV Healthcare - Glaxo's joint venture with Pfizer (PFE) and Shionogi - are likely to work and present an underappreciated risk to Gilead's (GILD) HIV franchise. Talks with investors lead Yee to believe few are even aware of this risk and that the consensus view is underestimating the probability these non-inferiority trials will work. Arguing that the consensus view should factor in more conservative assumptions for Gilead's HIV business post 2018 due to this risk, Yee cut his price target on Gilead to $95 from $105, but keeps an Outperform rating on the shares.
10/06/16
PIPR
10/06/16
NO CHANGE
Target $46
PIPR
Overweight
Piper thinks Alnylam failure is positive for Ionis
Piper Jaffay analyst Joshua Schimmer thinks Alnylam Pharmaceuticals' (ALNY) "abrupt halt" of revusiran for TTR cardiomyopathy is likely a positive for Ionis Pharmaceuticals' (IONS) transthyretin program. The move "knocks out a competitive drug" while Ionis and GlaxoSmithKline (GSK) remain on their previously indicated timeline, Schimmer tells investors in a research note. The analyst at this point believes Alnylam's setback will be limited to revusiran and not read-through to other Gal-Nac programs or other TTR cardiomyopathy or polyneuropathy programs. He keeps an Overweight rating on Ionis with a $46 price target,
11/09/16
SBSH
11/09/16
NO CHANGE
SBSH
Citi sees Healthcare 'relief rally' after Trump win
Citi analyst Andrew Baum expects a "'relief rally" to drive near-term sector outperformance for names in the Healthcare space given the "inability of the Democrats to attain the Presidency, the House or Congress." Longer term, however, the analyst still sees "significant continued legislative risk" for pharma reimbursement. Baum prefers GlaxoSmithKline (GSK), AstraZeneca (AZN), Shire (SHPG) and Roche (RHHBY) among European majors and Bristol-Myers (BMY) and Eli Lilly (LLY) in the U.S.
INVA Innoviva
$10.21

-0.13 (-1.26%)

10/31/16
COWN
10/31/16
UPGRADE
Target $15
COWN
Outperform
Innoviva upgraded to Outperform from Market Perform at Cowen
Cowen analyst Tyler Van Buren upgraded Innoviva to Outperform and raised its price target to $15 from $13 citing valuation discount and said the commercial prospects for Breo and Anoro remain stronger than ever heading into next year.

TODAY'S FREE FLY STORIES

APDN

Applied DNA Sciences

$1.76

0.36 (25.71%)

09:47
06/28/17
06/28
09:47
06/28/17
09:47
Syndicate
Applied DNA Sciences raises $1.8M in a private placement »

Applied DNA Sciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:45
06/28/17
06/28
09:45
06/28/17
09:45
General news
Pending Home Sales Index to be reported at 10:00 »

May Pending Home Sales…

SSNLF

Samsung

09:44
06/28/17
06/28
09:44
06/28/17
09:44
Hot Stocks
Samsung to open $380M home appliance plant in South Carolina »

Samsung announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MOMO

Momo

$37.06

-2.32 (-5.89%)

, BAC

Bank of America

09:40
06/28/17
06/28
09:40
06/28/17
09:40
Options
Unusually active option classes on open June 28th »

Unusual total active…

MOMO

Momo

$37.06

-2.32 (-5.89%)

BAC

Bank of America

JPM

JPMorgan

GOOGL

Alphabet Class A

$948.09

-24 (-2.47%)

XBI

SPDR S&P BIOTECH

C

Citi

P

Pandora

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 14

    Jul

  • 14

    Jul

  • 20

    Jul

  • 25

    Jul

  • 12

    Oct

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

AAP

Advance Auto Parts

09:39
06/28/17
06/28
09:39
06/28/17
09:39
Downgrade
Advance Auto Parts rating change  »

Follow up: Advance Auto…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRQR

ProQR Therapeutics

$5.03

-0.025 (-0.50%)

09:38
06/28/17
06/28
09:38
06/28/17
09:38
Syndicate
Breaking Syndicate news story on ProQR Therapeutics »

ProQR Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIS

General Mills

09:36
06/28/17
06/28
09:36
06/28/17
09:36
Technical Analysis
Technical View: General Mills trades higher after results and outlook »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 12

    Jul

SKYS

Sky Solar

$1.54

0.26 (20.31%)

09:35
06/28/17
06/28
09:35
06/28/17
09:35
Hot Stocks
Sky Solar engages lawyers to investigate conduct of former CEO »

Sky Solar Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

ADMS

Adamas Pharmaceuticals

$16.88

-0.51 (-2.93%)

09:35
06/28/17
06/28
09:35
06/28/17
09:35
Hot Stocks
Adamas Pharmaceuticals appoints Alfred Merriweather as CFO »

Adamas Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

UMC

UMC

09:35
06/28/17
06/28
09:35
06/28/17
09:35
Upgrade
UMC rating change  »

UMC upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:35
06/28/17
06/28
09:35
06/28/17
09:35
General news
U.S. NAR pending home sales preview: »

U.S. NAR pending home…

QCOM

Qualcomm

$55.43

-1.13 (-2.00%)

, NXPI

NXP Semiconductors

$109.52

-0.21 (-0.19%)

09:33
06/28/17
06/28
09:33
06/28/17
09:33
Recommendations
Qualcomm, NXP Semiconductors analyst commentary  »

Qualcomm could raise…

QCOM

Qualcomm

$55.43

-1.13 (-2.00%)

NXPI

NXP Semiconductors

$109.52

-0.21 (-0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBI

CB&I

09:33
06/28/17
06/28
09:33
06/28/17
09:33
Upgrade
CB&I rating change  »

CB&I upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAP

Advance Auto Parts

09:33
06/28/17
06/28
09:33
06/28/17
09:33
Downgrade
Advance Auto Parts rating change  »

Advance Auto Parts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACN

Accenture

09:32
06/28/17
06/28
09:32
06/28/17
09:32
Hot Stocks
Accenture acquires Intrepid, terms not disclosed »

Accenture has acquired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TM

Toyota

09:31
06/28/17
06/28
09:31
06/28/17
09:31
Downgrade
Toyota rating change  »

Toyota downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BEP

Brookfield Renewable

09:30
06/28/17
06/28
09:30
06/28/17
09:30
Downgrade
Brookfield Renewable rating change  »

Brookfield Renewable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVAL

Grupo Aval

09:30
06/28/17
06/28
09:30
06/28/17
09:30
Upgrade
Grupo Aval rating change  »

Grupo Aval upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YEXT

Yext

09:29
06/28/17
06/28
09:29
06/28/17
09:29
Conference/Events
Yext management to meet with Piper Jaffray »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

BANR

Banner Corp.

$54.58

0.64 (1.19%)

09:29
06/28/17
06/28
09:29
06/28/17
09:29
Hot Stocks
Banner Corp. announces special dividend of $1.00 per share »

Banner Corporation, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBD

Banco Bradesco

09:29
06/28/17
06/28
09:29
06/28/17
09:29
Upgrade
Banco Bradesco rating change  »

Banco Bradesco upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSTG

Pure Storage

09:28
06/28/17
06/28
09:28
06/28/17
09:28
Conference/Events
Pure Storage management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

VLY

Valley National

09:28
06/28/17
06/28
09:28
06/28/17
09:28
Initiation
Valley National initiated  »

Valley National initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

NEOS

Neos Therapeutics

$7.05

-0.3 (-4.08%)

09:27
06/28/17
06/28
09:27
06/28/17
09:27
Conference/Events
Neos Therapeutics management to meet with RBC Capital »

Group luncheon with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 27

    Jun

TCF

TCF Financial

09:27
06/28/17
06/28
09:27
06/28/17
09:27
Initiation
TCF Financial initiated  »

TCF Financial initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.